Company profile: PhoreMost
1.1 - Company Overview
Company description
- Provider of phenotypic screening and targeted protein degradation solutions, including the SITESEEKER® platform using PROTEINi® libraries to identify novel drug targets and druggable sites in live cells, and GlueSEEKER™ to discover molecular glue degraders. Offers an oncology-focused pipeline of first-in-class targets and E3 ligase-based degraders, and partnering services applying SITESEEKER® across therapeutic areas.
Products and services
- Targeted Protein Degradation: An E3 ligase–mediated therapeutic approach that employs the cell’s own machinery to tag disease-associated proteins for proteasomal destruction and selective degradation
- SITESEEKER® Platform: PhoreMost’s phenotypic screening platform uses PROTEINi® libraries to pinpoint novel drug targets and druggable sites across the human proteome in a live-cell context
- GlueSEEKER™ Platform: A library-based phenotypic screening technology employing insertional libraries to discover molecular glue degraders that induce proximity between target and effector proteins for targeted protein degradation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PhoreMost
Reveal Biosciences
HQ: United States
Website
- Description: Provider of computational pathology diagnostics using AI to analyze large whole slide microscope images, combining a histopathology laboratory with machine learning to diagnose disease. Offers a new class of diagnostics with fundamental improvements in reach, cost, speed, accuracy, and scale in disease diagnosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reveal Biosciences company profile →
SimplicityBio
HQ: Switzerland
Website
- Description: Provider of in-silico biomarker discovery programmes for companies and institutions, offering services in biomarker discovery and ranking, signature creation, and existent signature, delivering robust multi-biomarker signatures for the molecular diagnostic market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SimplicityBio company profile →
Ra Pharma
HQ: United States
Website
- Description: Provider of Cyclomimetics, a new drug class combining the diversity and specificity of antibodies with the benefits of small molecules; leveraging rapid generation of drug candidates to build a portfolio and partnerships focused on intracellular protein-protein interactions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ra Pharma company profile →
Femtogenix
HQ: United Kingdom
Website
- Description: Provider of next-generation DNA-interactive payload molecules for antibody-drug conjugates, discovered and developed via a platform that combines proprietary computational chemistry techniques with founder know-how from over 50 years of DNA-targeted drug experience. Founded in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Femtogenix company profile →
Fujifilm Cellular Dynamics
HQ: United States
Website
- Description: Provider of human induced pluripotent stem cell (iPSC)-derived cells for disease and preclinical research, including excitatory neurons, dopaminergic neurons, and GABAergic neurons (KCNT1, SCN1A KO). Offers CDMO services for contract development and cGMP manufacture of clinical-grade human cells, plus toxicity testing, stem cell banking, and cell therapy development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fujifilm Cellular Dynamics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PhoreMost
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PhoreMost
2.2 - Growth funds investing in similar companies to PhoreMost
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PhoreMost
4.2 - Public trading comparable groups for PhoreMost
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →